Analysts at BTIG Research initiated coverage on shares of
Histogenics Corporation HSGX with a Buy rating.
The target price for Histogenics is set to $13.
Histogenics' shares closed at $8.43 yesterday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
